Mylan intervenes to reverse federal court ruling preventing generic terfenadine; patent `129 at issue.
Executive Summary
MYLAN INTERVENES IN MMD v. KESSLER TERFENADINE CASE OVER PATENT `129 to protect the company's investment in a generic product to compete with what is now Hoechst Marion Roussel's nonsedating prescription antihistamine Seldane, according to papers filed with the D.C. federal court Sept. 29. Judge Royce Lamberth ruled Sept. 19 in favor of Hoechst, granting the company's motions for summary judgment and a preliminary injunction that prohibits FDA from approving any ANDAs for a generic form of terfenadine that does not include certification for patent #4,254,129.